Concert Pharmaceuticals (CNCE) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Intensity Materials Nature Nuclear Offset Package Packaging Pandemic Raw Materials Regenerative Toxic Waste Access Affordability Asian Benefits Black Community Culture Customer Cyber Cybersecurity Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Employee Retention Engagement Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Human Capital Incident Injuries Injury Minority Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Supplier Supply Chain Talent Union Women Workers Workforce Assessment Assurance Audit Bonus Chronic Classified Classified Board Commitment Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Pledging Poison Pill Proxy Contest Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

At the 2021 Annual Meeting of Stockholders of Concert Pharmaceuticals, Inc. (the “Company”) held on June 10, 2021, the Company’s stockholders voted as follows:
1. The stockholders elected the nominees listed below as Class I Directors to the Company’s Board of Directors, to serve until the Company’s 2024 Annual Meeting of Stockholders.

Nominees:	For:	Withheld:	Broker Non-Votes:

Peter Barton Hutt	12,788,217	4,409,630	7,557,058
Wilfred E. Jaeger, M.D.	13,611,699	3,586,148	7,557,058
Roger D. Tung, Ph.D.	13,759,416	3,438,431	7,557,058

2. The stockholders approved, on a non-binding, advisory basis, the Company’s executive compensation.


For:			15,201,561
Against:			1,968,570
Abstain:			27,716
Broker Non-Votes:			7,557,058

3. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.


For:			24,530,602
Against:			223,295
Abstain:			1,008